

Regimen Monograph

A - Regimen Name

VENE+OBIN Regimen

Venetoclax-Obinutuzumab

Disease Site Hematologic
Leukemia - Chronic Lymphocytic (CLL)

Intent Palliative

Regimen Category **Evidence-informed :**
Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR). Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.

This **Regimen Abstract** is an **abbreviated** version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.

Rationale and Uses For treatment of patients with previously untreated CLL
(Refer to the NDFP eligibility form and EAP for detailed funding criteria.)

**Supplementary
Public Funding**

[oBINutuzumab](#)

New Drug Funding Program (Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia) ([NDFP Website](#))

[venetoclax](#)

Exceptional Access Program (venetoclax - In Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia, based on criteria) ([EAP Website](#))

[back to top](#)

B - Drug Regimen

Cycle 1:

oBINutuzumab	1000 mg	IV	Days 1*, 8, 15
------------------------------	---------	----	----------------

*Dose may be split over 2 days (100 mg IV on day 1, then 900 mg IV on day 2)

venetoclax ¹	20 mg	PO	Days 22 to 28
---	-------	----	---------------

¹ Week 1 of venetoclax ramp-up period starts on cycle 1, day 22 and continues for 5 weeks (throughout cycle 2).

Cycle 2:

oBINutuzumab	1000 mg	IV	Day 1
venetoclax ²	50 mg	PO	Days 1 to 7
venetoclax	100 mg	PO	Days 8 to 14
venetoclax	200 mg	PO	Days 15 to 21
venetoclax	400 mg	PO	Days 22 to 28

² Weeks 2 to 5 of venetoclax ramp-up occurs during cycle 2.

Cycles 3 to 6:

oBINutuzumab	1000 mg	IV	Day 1
venetoclax ³	400 mg	PO	Days 1 to 28

³ Start of venetoclax maintenance dose.

See [VENE\(MNT\)](#) for Cycles 7 to 12 (24 weeks of venetoclax monotherapy).

[back to top](#)

C - Cycle Frequency

oBINutuzumab: REPEAT EVERY 28 DAYS for a usual total of 6 cycles, unless disease progression or unacceptable toxicity occurs.

venetoclax: CONTINUOUS treatment, with a 5-week ramp-up phase starting on day 22 of Cycle 1, followed by ten 28-day cycles starting with Cycle 3, unless disease progression or unacceptable toxicity occurs.

(Use regimen code [VENE\(MNT\)](#) for venetoclax treatment after stopping obinutuzumab.)

Refer to NDFP form for funding criteria for retreatment.

[back to top](#)

D - Premedication and Supportive Measures

Antiemetic Regimen: Minimal

[back to top](#)

J - Administrative Information

Venetoclax: Outpatient prescription for home administration

Obinutuzumab:

Approximate Patient Visit	4 hours
Pharmacy Workload (average time per visit)	18.249 minutes
Nursing Workload (average time per visit)	74.833 minutes

[back to top](#)

K - References

Eichhorst B, Niemann CU, Kater AP, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023 May 11;388(19):1739-54.

Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380:2225-36.

Fürstenau M, Kater AP, Robrecht S, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2024 Jun;25(6):744-59.

Obinutuzumab drug monographs. Ontario Health (Cancer Care Ontario).

Reimbursement recommendation: venetoclax and obinutuzumab. Canadian Journal of Health Technologies 2024;4(12).

Venetoclax drug monograph. Ontario Health (Cancer Care Ontario).

September 2025 Modified Rationale/uses and Cycle Frequency sections

[back to top](#)

M - Disclaimer

Regimen Abstracts

A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.

Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.

Regimen Monographs

Refer to the [New Drug Funding Program](#) or [Ontario Public Drug Programs](#) websites for the most up-to-date public funding information.

The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.

The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.

Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.

While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.

CCO and the Formulary's content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the Formulary.

[back to top](#)